Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Bristol-Myers dumps $1B-plus Alder deal, punts rheumatoid arthritis drug

Shares of Alder BioPharmaceuticals took a hit Tuesday morning after the biotech reported that Bristol-Myers Squibb had dumped its $1 billion-plus collaboration deal on the IL-6 drug clazakizumab, which had cleared a Phase IIb study for rheumatoid arthritis.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Want a window into the future of hepatitis C drug marketing? Keep an eye on Europe. Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

Pfizer, BMS pad bright Q2 with new FDA nod for Eliquis

Pfizer and Bristol-Myers Squibb's Eliquis has been lagging since launch time, trailing behind predecessors Pradaxa and Xarelto. But lately, the drugmakers' efforts have been paying off when it comes to market share, and a new indication may help keep the ball rolling.

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

BMS, Pfizer marketing efforts have Eliquis showing signs of life

Eliquis, the third entrant in the next-gen anticoagulant market, got off to a sluggish start. But now, marketers Bristol-Myers Squibb and Pfizer are pulling out all the stops when it comes to promoting the drug and expanding access

BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt

Eliquis, Pfizer and Bristol-Myers Squibb's new-age anticoagulant, got off to somewhat of a rocky start. The third entrant in the warfarin replacement market, the drug lagged well behind competitors last year, with EP Vantage estimating in October that analysts' 2014 sales estimates had fallen 60% within 12 months. Now, however, the drug is finally showing signs of life.

The top 15 late-stage blockbusters in the pipeline

In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd. Read the full report >>

Bristol-Myers is seeding a new crop of biotech spinouts, buyout options included

Bristol-Myers Squibb has formed a new joint venture with Boston-based Allied Minds that will hunt the groves of academia in an enterprising approach to launching new biotechs and bagging new drug candidates.

Bristol-Myers beats profit estimates, thanks to strong Yervoy, Eliquis numbers

Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.